Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

P210 Isolation frequency and abundance of Pseudomonas aeruginosa (Pa) in people with CF with chronic pseudomonas infection decreases following initiation of elexacaftor/tezacaftor/ivacaftor (ETI).

Autor: King, J.^1,2 (AUTHOR), Fenn, D.² (AUTHOR), Mossop, M.¹ (AUTHOR), Ish-Horowicz, J.¹ (AUTHOR), Rosenthal, M.² (AUTHOR), Ramadan, N.² (AUTHOR), Davies, J.^1,2 (AUTHOR)

Publikováno v: Journal of Cystic Fibrosis. 2024 Supplement 1, Vol. 23, pS133-S134. 2p.

Lumacaftor/ivacaftor changes the lung microbiome and metabolome in cystic fibrosis patients

Autor: Neerincx, Anne H., Whiteson, Katrine, Phan, Joann L., Brinkman, Paul, Abdel-Aziz, Mahmoud I., Weersink, Els J.M., Altenburg, Josje, Majoor, Christof J., Maitland-van der Zee, Anke H., Bos, Lieuwe D.J., Haarman, E., Rutjes, N. W., Terheggen-Lagro, S. W.J., Seljogi, D., Kemper, E. M., Lutter, R., Vijverberg, S. J., Vonk, S. E.M., Adriaens, N., Lub, R., van Brederode, M., van der Schaaf, L., Verkleij, M., van Gilst, N. A., Hofsteenge, G. H., Brackel, C. L.H., Lakeman, P., Bon, I. C.M., Tanner, S. P.M., Sterk, P. J., Longo, C., Sinha, A., Fenn, D., Lammers, A., Richards, L. B., van Bragt, J. M., Kos, R., Dagelet, J. W.F., Lone-Latif, S. J.A., Schultz, M. J., Smit, M. R., Hagens, L. A.

Publikováno v: Neerincx, A H, Whiteson, K, Phan, J L, Brinkman, P, Abdel-Aziz, M I, Weersink, E J M, Altenburg, J, Majoor, C J, Maitland-van der Zee, A H, Bos, L D J, Haarman, E, Rutjes, N W, Terheggen-Lagro, S W J, Seljogi, D, Kemper, E M, Lutter, R, Vijverberg, S J, Vonk, S E M, Adriaens, N, Lub, R, van Brederode, M, van der Schaaf, L, Verkleij, M, van Gilst, N A, Hofsteenge, G H, Brackel, C L H, Lakeman, P, Bon, I C M, Tanner, S P M, Sterk, P J, Longo, C, Sinha, A, Fenn, D, Lammers, A, Richards, L B, van Bragt, J M, Kos, R, Dagelet, J W F, Lone-Latif, S J A, Schultz, M J, Smit, M R, Hagens, L A, Amsterdam mucociliary clearance disease research group & Amsterdam UMC Breath Research Group 2021, ' Lumacaftor/ivacaftor changes the lung microbiome and metabolome in cystic fibrosis patients ', ERJ Open Research, vol. 7, no. 2, 00731-2020 . https://doi.org/10.1183/23120541.00731-2020
ERJ Open Research, 7(2):00731-2020. BMJ Publishing Group
ERJ Open Research
article-version (VoR) Version of Record
ERJ open research, 7(2):00731-2020. European Respiratory Society
ERJ Open Research, Vol 7, Iss 2 (2021)

Rationale Targeted cystic fibrosis (CF) therapy with lumacaftor/ivacaftor partly restores chloride channel function and improves epithelial fluid transport in the airways. Consequently, changes may occur in the microbiome, which is adapted to CF lung

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ab579d0ee582c686532e1520e3205a9
https://research.vumc.nl/en/publications/cdb44a8a-7c3d-44d5-8941-b1e909993ffb

Type Ia supernovae deflagration-to-detonation transition explosions powered by the Zel'dovich reactivity gradient mechanism.

Autor: Brooker, E, Plewa, T, Fenn, D

Publikováno v: Monthly Notices of the Royal Astronomical Society: Letters; Feb2021, Vol. 501 Issue 1, pL23-L27, 5p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.